Veröffentlichungen 2012

Publikationen

1. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [(68)Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with (18)F-FECH. Eur J Nucl Med Mol Imaging 2012;39:1085-1086.

2. Afshar-Oromieh A, Kratochwil C, Haberkorn U, Giesel FL. [Importance of PET/CT in lymphoma diagnostics]. Radiologe 2012;52(4):338-46.

3. Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, Podlesek D, Eisenhut M, Kratochwil C. Detection of cranial meningiomas: comparison of (68)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 2012;39:1409–1415.

4. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2012; [Epub ahead of print].

5. Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U. Antitumor Effects of Proteasome Inhibition in Anaplastic Thyroid Carcinoma. J Nucl Med 2012;53:1764-1771.

6. Askoxylakis V, Marr A, Altmann A, Markert A, Mier W, Debus J, Huber PE, Haberkorn U. Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Mol Imaging Biol 2012; [Epub ahead of print].

7. Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, Dimitrakopoulou-Strauss A, Kopp-Schneider A, Haberkorn U, Huber PE, Bischof M, Debus J, Thieke C. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol 2012;7:157. doi: 10.1186/1748-717X-7-157. 

8. Askoxylakis V, Ehemann V, Rana S, Krämer S, Rahbari NN, Debus J, Haberkorn U. Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX. Int J Mol Sci 2012;13(10):13030-48. doi: 10.3390/ijms131013030.

9. Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jaeger D. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. BMC Cancer 2012;12(1):108.

10. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, Neuhuber WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18:926-933.

11. Bonaterra GA, Zügel S, Thogersen J, Walter SA, Haberkorn U, Strelau J, Kinscherf R. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 2012;1(6):e002550. doi: 10.1161/JAHA.112.002550 [Epub ahead of print].

12. Bretschi M, Cheng C, Komljenovic D, Witt H, Dimitrakopoulou-Strauss A,Strauss LG, Semmler W, Baeuerle T. Cilengitide affects microenvironment, tumor compartment and vascularization in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analyses. Journal of Cancer Research and Clinical Oncology 2012, in print.

13. Breyer S, Semmler A, Miller T, Hill A, Geissler S, Haberkorn U, Mier W. Radioiodinated dechloro-4-iodofenofibrate: A hydrophobic model drug for molecular imaging studies. Int J Pharm 2012;431(1-2):78-83.

14. Cheng C, Alt V, Dimitrakopoulou-Strauss A, Pan L, Thormann U, Schnettler R, Weber K, Strauss LG. Evaluation of New Bone Formation in Normal and Osteoporotic Rats with a 3-mm Femur Defect: Functional Assessment with Dynamic PET-CT (dPET-CT) Using 2-Deoxy-2-[(18)F]Fluoro-D-glucose ( (18)F-FDG) and (18)F-Fluoride. Mol Imaging Biol 2012; [Epub ahead of print].

15. Dimitrakopoulou-Strauss A, Hohenberger P, Pan L, Kasper B, Roumia S, Strauss LG. Dynamic PET With FDG in Patients With Unresectable Aggressive Fibromatosis: Regression-Based Parametric Images and Correlation to the FDG Kinetics Based on a 2-Tissue Compartment Model. Clin Nucl Med 2012;37:943-948.

16. Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging 2012;12:283-289.

17. Eder M, Schaefer M, Bauder-Wuest U, Hull WE, Wängler C, Mier W, Haberkorn U, Eisenhut M. The 68Ga-complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23(4):688–697.

18. Giesel FL, Mehndiratta A, Mafomane MP, Zechmann CM, Bergmann F, Schemmer P, Haberkorn U, Kratochwil C. Cancer with unknown primary: finding a needle in a hay stack. Exp Oncol 2012;34(1):64-5.

19. Talanow R, Giesel F. Honoring our helpers. J Radiol Case Rep 2012;6(12):53-5. doi: 10.3941/jrcr.v6i12.1504.

20. Giesel FL, Mehndiratta A, Hempel A, Hempel E, Wuestenberg T, Kress KR, Essig M, Schröder J. Improvement of auditory hallucinations and reduction of primary auditory area's activation following TMS. Eur J Radiol 2012;81(6):1273-5.

21. Giesel FL, Kratochwil C, Mehndiratta A, Wulfert S, Moltz JH, Zechmann CM, Kauczor HU, Haberkorn U, Ley S. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 2012;81:2820-2825.

22. Giesel FL, Stefanova M, Schwartz L, Afshar-Oromieh A, Eisenhut M, Mier W, Haberkorn U, Kratochwil C. Impact of peptide receptor radionuclide therapy (PRRT) on the 68Ga-DOTATOC PET/CT uptake in normal tissue. Quartl J Nucl Med 2012; in print.

23. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, Hardt S, Lohse P, Ho AD, Haberkorn U, Dengler TJ, Altland K, Katus HA. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2012; [Epub ahead of print].

24. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Röcken C, Wanker EE, Dengler TJ, Altland K, Katus HA. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012;101(10):805-13.

25. Küntzelmann A, Guenther T, Haberkorn U, Essig M, Giesel F, Henze R, Schroeter ML, Schröder J, Schönknecht P. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization. Neurosci Lett 2012; pii: S0304-3940(12)01483-8. doi: 10.1016/j.neulet. [Epub ahead of print].

26. Lagemaat MW, Zechmann CM, Fütterer JJ, Weiland E, Lu J, Villeirs GM, Holshouser BA, van Hecke P, Lemort M, Schlemmer HP, Barentsz JO, Roell SO, Heerschap A, Scheenen TW. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T. J Magn Reson Imaging 2012;35(1):166-73.

27. Liu Y, Baeuerle T, Pan L, Dimitrakopoulou-Strauss A, Strauss LG, Heiss C, Schnettler R, Semmler W, Cao L. Calibration of cone beam CT using relative attenuation ratio for quantitative assessment of bone density. International Journal of Computer Assisted Radiology and Surgery 2012, in print.

28. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. The myristoylated preS1-domain of the hepatitis B virus L-protein mediates specific binding todifferentiated hepatocytes. Hepatology 2012; doi: 10.1002/hep.26181. [Epub ahead of print].

29. Michels T, Dölling R, Haberkorn U, Mier W. Acid-Mediated Prevention of Aspartimide Formation in Solid Phase Peptide Synthesis. Org Lett 2012;14(20):5218-21.

30. Raab MS, Breitkreutz I, Anderhub S, Ronnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res 2012;72(20):5374-5385.

31. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Müller OJ. AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2012; [Epub ahead of print].

32. Rana S, Nissen F, Marr A, Markert A, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V. Optimization of a Novel Peptide Ligand Targeting Human Carbonic Anhydrase IX. PLoS One 2012;7(5):e38279.

33. Sarko D, Eisenhut M, Haberkorn U, Mier W. Bifunctional Chelators in the Design and Application of Radiopharmaceuticals for Oncological Diseases. Curr Med Chem 2012;19(17):2667-2688.

34. Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2012;2(1):23. doi: 10.1186/2191-219X-2-23.

35. Schneider T, Puderbach M, Kunz J, Bischof A, Giesel FL, Dienemann H, Herth FJ, Schnabel PA, Safi S, Hoffmann H, Heussel CP. Simultaneous Computed Tomography-Guided Biopsy and Radiofrequency Ablation of Solitary Pulmonary Malignancy in High-Risk Patients. Respiration 2012;84:501-508 [Epub ahead of print].

36. Strauss LG, Koczan D, Seiz M, Tuettenberg T, Schmieder K, Pan L, Cheng C, Dimitrakopoulou-Strauss A. Correlation of the Ga-68-Bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas as Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays. Mol Imaging Biol 2012;14(3):376-83.

37. Strauss LG, Pan L, Cheng C, Dimitrakopoulou-Strauss A. F-18-Deoxyglucose (FDG) kinetics evaluated by a non-compartment model based on a linear regression function using a computer based simulation: correlation with the parameters of the two-tissue compartment model. AJNMMI 2012;2(4):448-457.

38. Strauss LG, Frangos S, Dimitrakopoulou-Strauss A. Response of calcitonin levels due to positron emission tomography with (18)F-FDG. Hell J Nucl Med 2012;15(3):251.

39. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Pan L, Hohenberger P. Correlation of Dynamic PET and Gene Array Data in Patients with Gastrointestinal Stromal Tumors. ScientificWorldJournal 2012;2012:721313 [Epub ahead of print].

40. Takesh M, Haberkorn U, Strauss LG, Roumia S, Dimitrakopoulou-Strauss A. Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography. Hell J Nucl Med 2012;15(1): 63-65.

41. Takesh M, Odat Allh K, Adams S, Zechmann C. Clinical Study. Diagnostic Role of 18F-FECH-PET/CT Compared with Bone Scan in Evaluating the Prostate Cancer Patients Referring with Biochemical Recurrence. International Scholarly Research Network. ISRN Oncol 2012;2012:815234 12 pages. doi: 10.5402/2012/815234.

42. Takesh M. The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology. ISRN Oncol 2012;2012:349351. doi: 10.5402/2012/349351.

43. Talanow R, Giesel F. Honoring our helpers. J Radiol Case Rep 2012;6(12):53-5. doi: 10.3941/jrcr.v6i12.1504.

44. Thiemann M, Oertel S, Ehemann V, Weichert W, Stenzinger A, Bischof M, Weber KJ, Lopez Perez R, Haberkorn U, Kulozik A, Debus J, Huber PE, Battmann C. In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol 2012;7:52. doi: 10.1186/1748-717X-7-52.

45. Zechmann CM, Traine L, Meißner T, Wagner-Gund B, Giesel FL, Goldschmidt H, Delorme S, Hillengass J. Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma: A technique to evaluate angiogenic response to therapy ? Acad Radiol 2012;19:100-108.

46. Zechmann CM, Menze BH, Kelm BM, Zamecnik P, Ikinger U, Giesel FL, Thieke C, Delorme S, Hamprecht FA, Bachert P. Automated vs. Manual Pattern Recognition of 3D (1)H MRSI Data of Patients with Prostate Cancer. Acad Radiol 2012;19(6):675-84.

47. Zoller F, Schwaebel, T, Markert A, Haberkorn U, Mier W. Engineering and functionalization of the disulfide-constrained miniprotein Min-23 as a scaffold for diagnostic application. ChemMedChem 2012;7:237-247.

48. Zoller F, Markert A, Barthe P, Zhao W, Weichert W, Askoxylakis V, Altmann A, Mier W, Haberkorn U. Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumor-targeting Miniproteins. Angew Chem Int Ed Engl 2012;51(52):13136-9. doi: 10.1002/anie.201203857.

Buchbeiträge

1. Haberkorn U. Radiolabeled Drugs or the Use of Surrogate Biomarkers to Evaluate New Anticancer-Agents. In: Elsinga PH, van Waarde A, Paans AMJ, Dierckx RAJO. Trends on the Role of PET in Drug Development. World Scientific Publishing, New Jersey 2012, pp 447-505. ISBN 9789814317733.

2. Mehndiratta A, Knopp MV, Giesel FL. Magnetic Resonance Angiography: Review of Clinical Applications. In: Magnetic Resonance Angiography Basics to Future. Shabana W (ed.). InTech 2012. pp 23-38. ISBN 9789535104018.

3. Mehndiratta A, Prabu A, Kashyap R, Giesel FL. Acute Nutritional Emergencies. In: Emergency Medicine Manual (in print).

4. Mehndiratta A, Prabu A, Zechmann C, Giesel FL. Nuclear Medicine: An overview of Imaging Techniques, Clinical Applications and Trials. In: Therapeutic Specifics of Medical Imaging. Schwartz L (ed.). Springer (invited).

5. von Tengg-Kobligk H, Mehndiratta A, Giesel F. Contrast Agents in Radiology. In: Therapeutic Specifics of Medical Imaging. Schwartz L (ed.). Springer (invited).

6. Zechmann C. Kapitel Radiologie. In: Mediscript . Hammerexamen 10/2006 –10/2011 Alle Original-IMPP-Prüfungsfragen des 2. Abschnitts der Ärztlichen Prüfung, CD-Rom. Urban & Fischer bei Elsevier; 1. Auflage 2012; ISBN 9783437330100.

7. Zechmann C. Kapitel Radiologie. In: Mediscript . Hammerexamen 10/2006 –4/2012. Alle Original-IMPP-Prüfungsfragen des 2. Abschnitts der Ärztlichen Prüfung, CD-Rom. Urban & Fischer bei Elsevier; 1. Auflage 2012; ISBN 9783437330100.

Buch

1. Wetzke M, Happle C, Giesel FL, Zechmann CM, (eds.) Basics Bildgebende Verfahren. Urban & Fischer Verlag in Elsevier GmbH 3. Auflage, Erscheinungsdatum: 12.12.2012. ISBN 9783437422881.

nach oben
powered by webEdition CMS